1. At a Glance – The Chemist Shop That Prints Cash
₹4,489 per share.
Market cap: ₹10,339 crore.
Stock P/E: 44.
ROCE: 152%.
ROE: 113%.
Debt-to-equity: 0.06.
Dividend yield: 1.23%.
Ladies and gentlemen, meet Sanofi Consumer Healthcare India Ltd — a 2023-born demerger baby that already behaves like it owns half your medicine cabinet.
Q4 FY25 numbers?
Revenue ₹2,510 mn (+47%).
PAT ₹665 mn (+50%).
Full-year FY25 revenue ₹8,784 mn.
Full-year PAT ₹2,401 mn.
Operating margins steady at 36%. Inventory days collapsed from 232 to 80. Cash conversion cycle? Negative.
This is the kind of business where you sneeze, they earn. You get a headache, they earn. You forget Vitamin D, they earn.
But here’s the real question:
At 44× earnings and 26.9× book value… are we paying for healthcare stability — or for brand nostalgia?
Let’s open the strip and read the label.
2. Introduction – The Demerger Drama Nobody Prescribed
In 2023, this business was carved out from Sanofi India to become a standalone Consumer Healthcare company.
Translation?
The boring but stable OTC brands were separated from the high-risk biopharma experiments.
And guess what? OTC won.
They sell:
- Combiflam (pain relief royalty)
- Allegra (allergy warrior)
- Avil
- DePURA (Vitamin D glow-up)
India contributes 91% of revenue. Exports are just 9%. So this is very much a desi cough-and-cold story.
Then came the corporate drama:
- Open offer by Opal Bidco SAS for 26% stake
- Promoter holding jumped to 71.27%
- Sanofi sold 50% stake in Opella globally
- CFO resigned in Oct 2025
- New CFO appointed same month
- New SMPs designated Feb 2026
Corporate governance musical chairs? Or just normal multinational restructuring?
You tell me.
3. Business Model – WTF Do They Even Do?
Let’s simplify.
They sell products you buy without a doctor’s prescription.
Pain? Combiflam.
Allergy? Allegra.
Vitamin D deficiency? DePURA.
They don’t manufacture everything themselves. They use third-party manufacturers. Classic asset-light model.
Revenue mix FY24:
- Product sales: 91%
- Services: 6%
- Interest income: 2%
Distribution:
- Distributors
- Wholesalers
- Hospitals
- Pharmacies
- E-commerce
- Government institutions
They operate across 29 Indian states and 2 overseas countries.
This is not a research lab.
This is a brand monetisation machine.
They don’t need to invent a molecule.
They need to ensure you
